Meeder Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Meeder Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,685	Closed	-$5K	–	2588
2020 Q1	$5K	Buy	1,685 +991	+143%	+$3.66K	﹤0.01%	1826
2019 Q4	$3K	Buy	694 +139	+25%	+$482	﹤0.01%	1962
2019 Q3	$2K	Buy	+555	New	+$2.22K	﹤0.01%	2007
2019 Q2	–	Sell	-355	Closed	-$2K	–	2179
2019 Q1	$2K	Sell	355 -248	-41%	-$1.6K	﹤0.01%	1587
2018 Q4	$3K	Buy	603 +270	+81%	+$2.05K	﹤0.01%	1536
2018 Q3	$3K	Buy	+333	New	+$3.36K	﹤0.01%	1418
2017 Q2	–	Sell	-979	Closed	-$19K	–	1939
2017 Q1	$19K	Sell	979 -78	-7%	-$1.23K	﹤0.01%	736
2016 Q4	$16K	Buy	+1,057	New	+$13.7K	﹤0.01%	688

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Meeder Asset Management's PRTK Position: Q2 2020 in Review

Meeder Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2020, closing a stake of 1,685 shares — an estimated $5K sold.

Meeder Asset Management first reported a position in PRTK in Q4 2016 and held it in 8 quarters. The position peaked at $19K in Q1 2017. 99 funds tracked by Wall St. Rank hold PRTK as of Q2 2020.

Meeder Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 1,685 Paratek Pharmaceuticals, Inc. shares in Q2 2020, an estimated $5K.
Meeder Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2016 and held it in 8 quarters.
Meeder Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $19K in Q1 2017.
99 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.